Johnson & Johnson (JNJ) Stock Analysis
Is JNJ a good investment?
Johnson & Johnson (JNJ) has a Plutrex AI rating of 60.0/100 as of October 10, 2026, indicating a Hold consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Balance sheet fortress + FCF supremacy: D/E 0.44x (48% below 0.85x industry average), $20.76B cash, $18.71B annual FCF, and 64 consecutive years of dividend growth — a Dividend King with unmatched financial resilience and M&A optionality to offset Stelara biosimilar erosion that peers carrying 0.84x D/E cannot replicate. Main concern: Valuation premium vs. growth delivery: PEG 3.07x remains nearly triple the 1.0-1.5x fair value threshold; historical earnings growth -0.9% YoY must inflect to +10.4% next year to justify P/E 30.30x; analyst consensus target $290.62 implies only 11.2% upside — thin margin of safety; Stelara biosimilar headwind is the central risk to the required earnings acceleration.
Investment Summary
Johnson & Johnson (JNJ) at $261.44 is a world-class business trading at a meaningful premium to intrinsic value, making it a HOLD with patient accumulation in the $248-$265 zone. The quality profile is exceptional: gross margin 68.0%, operating margin 29.2%, net margin 21.5% (27.8% above the 16.81% industry average), ROE 25.7%, D/E 0.44x (48% below the 0.85x peer average), $20.76B cash, and $18.71B annual FCF. However, the valuation math remains unfavorable: PEG 3.07x (vs. 1.0-1.5x fair value threshold, though 35.9% below the industry's 4.79x average), P/E 30.30x on only 9.9% five-year EPS growth, and historical earnings growth of -0.9% YoY that must reverse to +10.4% next year to justify consensus. The stock has declined 3.6% since our prior report ($271.22 → $261.44), modestly improving the risk/reward — analyst consensus target $290.62 now implies 11.2% upside vs. 7.4% previously. News is constructive (sentiment 77/100): 64 consecutive years of dividend growth cements Dividend King status, and the 2030 growth prediction headline signals improving long-term narrative, though biosimilar competition on Stelara remains the primary near-term revenue headwind. Entry zone maintained at $248-$265; at $256 midpoint, implied upside to $290.62 is 13.5%, approaching adequate compensation for this quality compounder.
Key Strengths
- Balance sheet fortress + FCF supremacy: D/E 0.44x (48% below 0.85x industry average), $20.76B cash, $18.71B annual FCF, and 64 consecutive years of dividend growth — a Dividend King with unmatched financial resilience and M&A optionality to offset Stelara biosimilar erosion that peers carrying 0.84x D/E cannot replicate
- Net margin leadership and profitability moat: 21.5% net margin (+27.8% above 16.81% industry average), ROE 25.7% at parity with peers despite using dramatically less leverage (0.44x vs. 0.85x D/E), and 68% gross margin reflecting durable patent-protected pricing power — structural competitive advantages of a wide-moat compounder
- Relative valuation advantage vs. peers: PEG 3.07x is 35.9% BELOW the 4.79x industry average, meaning JNJ is actually the relatively cheaper option on growth-adjusted terms within its peer group — a counterintuitive finding that partially offsets the absolute overvaluation concern
Key Concerns
- Valuation premium vs. growth delivery: PEG 3.07x remains nearly triple the 1.0-1.5x fair value threshold; historical earnings growth -0.9% YoY must inflect to +10.4% next year to justify P/E 30.30x; analyst consensus target $290.62 implies only 11.2% upside — thin margin of safety; Stelara biosimilar headwind is the central risk to the required earnings acceleration
- Structural growth laggard in a high-growth peer group: Revenue growth 6.6% vs. 17.35% industry average (-62% deficit); forward EPS growth 10.4% vs. 141.63% industry average next year (-92.7% deficit); JNJ projects only 7.3% of peer group's forward EPS growth — growth investors have far more compelling alternatives within the same pharmaceutical sector
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
JNJ's fundamentals present a classic 'magnificent business, challenging price' dilemma. Profitability is elite-tier: gross margin 68.0% (vs. 71.28% industry average — slight deficit, but industry skewed by pure-play biotech), operating margin 29.2% (vs. 30.70% peers, -4.9% gap), net margin 21.5% (vs. 16.81% peers, +27.8% advantage driven by conservative 0.44x D/E reducing interest burden), and ROE 25.7% (vs. 25.38% peers — parity, but achieved with far less leverage, implying higher quality). Financial health is fortress-grade: D/E 0.44x (vs. 0.85x industry average, -48.2% leverage discount), $20.76B cash, $18.71B FCF — FCF alone could retire all debt in under one year. The critical weakness is growth: revenue +6.6% YoY (vs. 17.35% industry, -62% deficit), earnings -0.9% YoY (vs. +49.39% industry, -101.8% deficit), forward EPS +10.4% next year (vs. 141.63% industry average — JNJ generates only 7.3% of peer projected growth). PEG 3.07x is elevated in absolute terms but actually 35.9% below the 4.79x industry average — the entire pharmaceutical sector is expensive. P/E 30.30x on ~10% growth is the core valuation tension. Intrinsic value using 15x FCF ($18.71B) plus net cash = ~$280B enterprise value, suggesting the stock is modestly overvalued at current $~630B market cap.
News Sentiment
Johnson & Johnson is navigating a pivotal chapter in its storied history, balancing a formidable legacy of financial strength against mounting competitive pressures in its pharmaceutical business. The company's 64-year streak of consecutive dividend increases — earning it 'Dividend King' status — continues to make headlines, with recent coverage asking 'Does That Make It a Buy?' and 'Can It Weather a Downturn?' The answer from analysts is nuanced: JNJ's fortress balance sheet and $18.7 billion in annual free cash flow make it a premier defensive holding, but its days as a growth powerhouse are being tested. The most pressing challenge is biosimilar competition threatening its blockbuster immunology drug Stelara, which has been a major revenue driver. However, J&J is fighting back — its immunology portfolio, anchored by Tremfya, is showing clinical differentiation that could fill the Stelara void. One headline boldly predicts 'Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Expect,' reflecting cautious optimism that pipeline execution and medical device strength will accelerate earnings growth from the current -0.9% YoY toward the projected 10.4% next year. Earnings surprise history is also drawing attention, with analysts examining whether JNJ can beat estimates in its upcoming quarterly report — a pattern that has historically supported the stock. For dividend investors seeking stability in uncertain markets, JNJ remains a cornerstone holding. For growth-oriented investors, patience is required as the company works through its biosimilar transition.
Risk Assessment
PRIMARY RISK: Stelara biosimilar competition could erode pharmaceutical revenues faster than pipeline catalysts (TREMFYA label expansion, Caplyta, RYBREVANT) compensate, making the required +10.4% next-year EPS acceleration unachievable and triggering a valuation de-rating from P/E 30.30x toward 24-26x, implying downside to $215-$230. SECONDARY RISK: Pharmaceutical pricing pressure from regulatory/policy headwinds could compress gross margins from 68% toward 64-65%, reducing FCF below $16B and undermining the dividend growth narrative. MITIGATION: The $20.76B cash position and $18.71B FCF provide extraordinary buffer against near-term headwinds — JNJ can sustain dividend growth and execute bolt-on acquisitions even with 15-20% revenue erosion on Stelara. Stop at $241 (~6% below $256.50 entry midpoint) protects against a meaningful valuation re-rating while allowing normal volatility. 64 consecutive years of dividend growth and D/E 0.44x mean balance sheet risk is minimal — the primary risk is multiple compression, not fundamental impairment.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is JNJ a halal stock?
Yes, Johnson & Johnson (JNJ) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for JNJ?
Johnson & Johnson (JNJ) has a Plutrex AI rating of 60.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is JNJ a good investment?
According to Plutrex AI, JNJ has a Hold rating (60.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in JNJ?
US stocks like JNJ can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in JNJ?
Plutrex AI identifies the main risks for JNJ by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.